P47 | UTILITY AND SENSITIVITY OF WETT-SA53 TO MEASURE DYSGEUSIA ASSOCIATED WITH TALQUETAMAB, A GPRC5D×CD3 BISPECIFIC ANTIBODY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: PRELIMINARY DATA FROM THE TALISMAN STUDY

Introduction. Talquetamab (Tal) is a GPRC5D×CD3 bispecific antibody approved for the treatment of relapsed/refractory multiple myeloma (RRMM). Early oral adverse event (AEs) onset, including dysgeusia, can impact patient (pt) quality of life. The TALISMAN study aims to better understand oral AEs be...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	R. Popat, N.W.C.J. Van De Donk, B. Faiman, J. Yuda, K. Kim, A. Costa, A. Laheij, R.L. Doty, J. Omel, B. Lipe, L. Sanchez, A. Chari, A. Lin, H. Sroussi, M. Fernandez, K.S. Gray, G. Aguilar, K. Bolyard, J. Schultz, K. Qi, D. Cortes-Selva, J. Zhang, C. Heuck, K. Hawks, K. Tian, M. França, L. Rasche
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Ferrata Storti Foundation 2026-04-01
Sarja:	Haematologica
Linkit:	https://haematologica.org/article/view/14053
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!